TargetBeta
KIT
KIT proto-oncogene, receptor tyrosine kinase · also CD117, SCFR, C-Kit, PBT · CD molecules
15 programs in company-led studies act on KIT, from 13 companies: 8 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (12 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 404 running | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | ChEMBL |
| imatinibrule | Novartis | phase 4 | 703 running | ABL1, BCR, PDGFRB | ChEMBL |
| Avapritinibrule | Sanofi | phase 4 | 102 running | PDGFRA | NCIt |
| velzatinib | GlaxoSmithKline | phase 3 | 88 running | – | the company's pipeline |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 407 running | FLT4, KDR, PDGFRB | ChEMBL |
| quizartinibrule | Daiichi Sankyo | phase 3 | 225 running | CSF1R, FLT3, PDGFRA, PDGFRB, RET | ChEMBL |
| masitinibrule | AB Science | phase 3 | 384 running | FGFR3, PDGFRA, PDGFRB | ChEMBL |
| ripretinibrule | Ono Pharmaceutical | phase 3 | 93 running | PDGFRA | NCIt |
| seralutinibrule | GB002, Inc., a wholly owned subsidiary of Gossamer Bio | phase 3 | 82 running | CSF1R, PDGFRA, PDGFRB | ChEMBL |
| elenestinib | Sanofi | phase 3 | 31 running | – | the company's pipeline |
| NB-003rule | Ningbo Newbay Technology Development | phase 3 | 21 running | – | NCIt |
| BLU-808 | Sanofi | phase 2 | 31 running | – | the company's pipeline |
| THB335rule | Calixis | phase 2 | 21 running | – | the studies' text |
| briquilimabrule | Jasper Therapeutics | phase 2 | 70 running | – | NCIt |
| Anti-c-Kit/MMAE Antibody-Drug Conjugate NN3201rule | Novelty Nobility | phase 1 | 11 running | – | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Gastrointestinal Stromal Tumors, 6 programs
- Chronic Urticaria, 3 programs
- Asthma, 2 programs
- Leukemia, Myeloid, Acute, 2 programs
- Mastocytosis, Systemic, 2 programs
- Neoplasms, 2 programs
- Pulmonary Arterial Hypertension, 2 programs
- Alzheimer Disease, 1 program
- Amyotrophic Lateral Sclerosis, 1 program
- Arthritis, Rheumatoid, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026seralutinib · GB002, Inc., a wholly owned subsidiary of Gossamer Bio · phase 3 · NCT06274801
- Dec 31, 2026BLU-808 · Sanofi · phase 2 · NCT06931405
- Jan 12, 2027velzatinib · GlaxoSmithKline · phase 3 · NCT07862114
- Mar 31, 2027anlotinib · Sino Biopharmaceutical · phase 3 · NCT07438886
- May 1, 2027quizartinib · Daiichi Sankyo · phase 3 · NCT03793478
- Jun 23, 2027Avapritinib · Sanofi · phase 4 · NCT03731260
- Aug 30, 2027Anti-c-Kit/MMAE Antibody-Drug Conjugate NN3201 · Novelty Nobility · phase 1 · NCT06805825
- Sep 30, 2027regorafenib · Bayer · phase 4 · NCT02955940
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.